Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

The Clinical Impact of a Negative Molecular β-Lactamase Gene Test for Enterobacteriaceae: Let's Not Let Perfect Be the Enemy of Really Good.

Pogue JM, Heil EL.

J Clin Microbiol. 2020 Mar 25;58(4). pii: e02098-19. doi: 10.1128/JCM.02098-19. Print 2020 Mar 25. No abstract available.

PMID:
32213578
2.

Cefiderocol: A Novel Agent for the Management of Multidrug-Resistant Gram-Negative Organisms.

Wu JY, Srinivas P, Pogue JM.

Infect Dis Ther. 2020 Mar;9(1):17-40. doi: 10.1007/s40121-020-00286-6. Epub 2020 Feb 18. Review.

3.

What Is Your Diagnosis?

Pogue JM, Gilmour LJ, Kieves NR.

J Am Vet Med Assoc. 2020 Jan 15;256(2):171-173. doi: 10.2460/javma.256.2.171. No abstract available. Erratum in: J Am Vet Med Assoc. 2020 Mar 15;256(6):659.

PMID:
31910077
4.

Reply to Vena, et al.

Pogue JM, Kaye KS, Bonomo RA, Perez F.

Clin Infect Dis. 2020 Jan 6. pii: ciaa004. doi: 10.1093/cid/ciaa004. [Epub ahead of print] No abstract available.

PMID:
31904808
5.

Carbapenem-Susceptible Klebsiella pneumoniae and Escherichia coli Isolates Carrying a Truncated KPC Carbapenemase: a Challenge for Rapid Molecular Diagnostics.

Salimnia H, Veltman J, Chandrasekar PH, Pogue JM, Mynatt R, Salimnia T, Marshall SH, Hujer AM, Bonomo RA.

J Clin Microbiol. 2020 Feb 24;58(3). pii: e01627-19. doi: 10.1128/JCM.01627-19. Print 2020 Feb 24. No abstract available.

PMID:
31852760
6.

Clinical Implications of Microbiologic Treatment Failure in the Setting of Clinical Cure of Bacterial Pneumonia.

Albin OR, Henig O, Patel TS, Valley TS, Pogue JM, Petty LA, Mills JP, Brancaccio A, Martin ET, Kaye KS.

Clin Infect Dis. 2019 Dec 13. pii: ciz1187. doi: 10.1093/cid/ciz1187. [Epub ahead of print]

PMID:
31832641
7.

Polymyxin Susceptibility Testing and Interpretive Breakpoints: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST).

Pogue JM, Jones RN, Bradley JS, Andes DR, Bhavnani SM, Drusano GL, Dudley MN, Flamm RK, Rodvold KA, Ambrose PG.

Antimicrob Agents Chemother. 2020 Jan 27;64(2). pii: e01495-19. doi: 10.1128/AAC.01495-19. Print 2020 Jan 27.

PMID:
31767718
8.

Relationship Status between Vancomycin Loading Dose and Treatment Failure in Patients with MRSA Bacteremia: It's Complicated.

Ortwine JK, Zasowski EJ, Pogue JM, Hanni C, Giuliano C, Casapao AM, Mynatt R, Rybak MJ.

Infect Dis Ther. 2019 Dec;8(4):627-640. doi: 10.1007/s40121-019-00268-3. Epub 2019 Oct 21.

9.

Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas Aeruginosa.

Pogue JM, Kaye KS, Veve MP, Patel TS, Gerlach AT, Davis SL, Puzniak LA, File TM, Olson S, Dhar S, Bonomo RA, Perez F.

Clin Infect Dis. 2019 Sep 23. pii: ciz816. doi: 10.1093/cid/ciz816. [Epub ahead of print]

PMID:
31545346
10.

Laces out Dan! The role of tazobactam based combinations for invasive ESBL infections in a post-MERINO world.

Pogue JM, Heil EL.

Expert Opin Pharmacother. 2019 Dec;20(17):2053-2057. doi: 10.1080/14656566.2019.1663827. Epub 2019 Sep 8. No abstract available.

PMID:
31496320
11.

Toxicity in Patients.

Pogue JM, Tam VH.

Adv Exp Med Biol. 2019;1145:289-304. doi: 10.1007/978-3-030-16373-0_17. Review.

PMID:
31364083
12.

Analysis of Pooled Phase III Efficacy Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections.

Giordano PA, Pogue JM, Cammarata S.

Clin Infect Dis. 2019 Apr 8;68(Suppl 3):S223-S232. doi: 10.1093/cid/ciz006.

13.

Open-Label Randomized Trial of Early Clinical Outcomes of Ceftaroline Fosamil Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections at Risk of Methicillin-Resistant Staphylococcus aureus.

Claeys KC, Zasowski EJ, Trinh TD, Casapao AM, Pogue JM, Bhatia N, Mynatt RP, Wilson SS, Arthur C, Welch R, Sherwin R, Hafeez W, Levine DP, Kaye KS, Delgado G, Giuliano CA, Takla R, Rieck C, Johnson LB, Murray KP, Gordon J, Reyes K, Hartman P, Davis SL, Rybak MJ.

Infect Dis Ther. 2019 Jun;8(2):199-208. doi: 10.1007/s40121-019-0242-5. Epub 2019 Mar 27.

14.

Effects of blood pressure and lipid lowering on cognition: Results from the HOPE-3 study.

Bosch J, O'Donnell M, Swaminathan B, Lonn EM, Sharma M, Dagenais G, Diaz R, Khunti K, Lewis BS, Avezum A, Held C, Keltai M, Reid C, Toff WD, Dans A, Leiter LA, Sliwa K, Lee SF, Pogue JM, Hart R, Yusuf S; HOPE-3 Investigators.

Neurology. 2019 Mar 26;92(13):e1435-e1446. doi: 10.1212/WNL.0000000000007174. Epub 2019 Feb 27.

15.

Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections.

Eljaaly K, Alharbi A, Alshehri S, Ortwine JK, Pogue JM.

Drugs. 2019 Feb;79(3):243-269. doi: 10.1007/s40265-019-1054-3. Review.

PMID:
30723876
16.
17.

The hypothetical impact of Accelerate Pheno™ system on time to effective therapy and time to definitive therapy in an institution with an established antimicrobial stewardship programme currently utilizing rapid genotypic organism/resistance marker identification.

Henig O, Cooper CC, Kaye KS, Lephart P, Salimnia H, Taylor M, Hussain N, Hussain Z, Deeds K, Hayat U, Patel J, Pogue JM.

J Antimicrob Chemother. 2019 Jan 1;74(Supplement_1):i32-i39. doi: 10.1093/jac/dky533.

18.

The Hypothetical Impact of Accelerate Pheno on Time to Effective Therapy and Time to Definitive Therapy for Bloodstream Infections Due to Drug-Resistant Gram-Negative Bacilli.

Henig O, Kaye KS, Chandramohan S, Cooper CC, Lephart P, Salimnia H, Taylor M, Pogue JM.

Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e01477-18. doi: 10.1128/AAC.01477-18. Print 2019 Mar.

19.

Epidemiology of Diabetic Foot Infection in the Metro-Detroit Area With a Focus on Independent Predictors for Pathogens Resistant to Recommended Empiric Antimicrobial Therapy.

Henig O, Pogue JM, Cha R, Kilgore PE, Hayat U, Ja'ara M, Ali RM, Mahboob S, Pansare R, Deeds K, Joarder B, Kandala H, Dhar S, Kaye KS.

Open Forum Infect Dis. 2018 Sep 27;5(11):ofy245. doi: 10.1093/ofid/ofy245. eCollection 2018 Nov.

20.

Making the change to area under the curve-based vancomycin dosing.

Heil EL, Claeys KC, Mynatt RP, Hopkins TL, Brade K, Watt I, Rybak MJ, Pogue JM.

Am J Health Syst Pharm. 2018 Dec 15;75(24):1986-1995. doi: 10.2146/ajhp180034. Epub 2018 Oct 17. No abstract available.

PMID:
30333114
21.

Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae.

Petty LA, Henig O, Patel TS, Pogue JM, Kaye KS.

Infect Drug Resist. 2018 Sep 12;11:1461-1472. doi: 10.2147/IDR.S150447. eCollection 2018. Review.

22.

Averting the post-antibiotic era: successful use of meropenem/vaborbactam for carbapenem-resistant Serratia marcescens and Enterobacter aerogenes bacteraemia in a haemodialysis patient.

Jorgensen SCJ, McDonald P, Mynatt RP, Pogue JM, Lerner SA, Dhar S, Salimnia H, Rybak MJ.

J Antimicrob Chemother. 2018 Dec 1;73(12):3529-3531. doi: 10.1093/jac/dky346. No abstract available.

PMID:
30188993
23.

Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations.

Pogue JM, Bonomo RA, Kaye KS.

Clin Infect Dis. 2019 Jan 18;68(3):519-524. doi: 10.1093/cid/ciy576. Review.

PMID:
30020449
24.

Ceftazidime/avibactam versus standard-of-care agents against carbapenem-resistant Enterobacteriaceae harbouring blaKPC in a one-compartment pharmacokinetic/pharmacodynamic model.

Barber KE, Pogue JM, Warnock HD, Bonomo RA, Kaye KS.

J Antimicrob Chemother. 2018 Sep 1;73(9):2405-2410. doi: 10.1093/jac/dky213.

25.

Meropenem-vaborbactam: a new weapon in the war against infections due to resistant Gram-negative bacteria.

Patel TS, Pogue JM, Mills JP, Kaye KS.

Future Microbiol. 2018 Jul;13:971-983. doi: 10.2217/fmb-2018-0054. Epub 2018 Apr 25.

26.

An Antibiotic Stewardship Program Blueprint for Optimizing Verigene BC-GN within an Institution: a Tale of Two Cities.

Pogue JM, Heil EL, Lephart P, Johnson JK, Mynatt RP, Salimnia H, Claeys KC.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02538-17. doi: 10.1128/AAC.02538-17. Print 2018 May.

27.

The Verigene dilemma: gram-negative polymicrobial bloodstream infections and clinical decision making.

Claeys KC, Heil EL, Pogue JM, Lephart PR, Johnson JK.

Diagn Microbiol Infect Dis. 2018 Jun;91(2):144-146. doi: 10.1016/j.diagmicrobio.2018.01.012. Epub 2018 Feb 2.

PMID:
29449043
28.

Identification of Vancomycin Exposure-Toxicity Thresholds in Hospitalized Patients Receiving Intravenous Vancomycin.

Zasowski EJ, Murray KP, Trinh TD, Finch NA, Pogue JM, Mynatt RP, Rybak MJ.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01684-17. doi: 10.1128/AAC.01684-17. Print 2018 Jan.

29.

A Quasi-Experiment To Study the Impact of Vancomycin Area under the Concentration-Time Curve-Guided Dosing on Vancomycin-Associated Nephrotoxicity.

Finch NA, Zasowski EJ, Murray KP, Mynatt RP, Zhao JJ, Yost R, Pogue JM, Rybak MJ.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01293-17. doi: 10.1128/AAC.01293-17. Print 2017 Dec.

30.

Intravenous fosfomycin for the treatment of hospitalized patients with serious infections.

Shorr AF, Pogue JM, Mohr JF.

Expert Rev Anti Infect Ther. 2017 Oct;15(10):935-945. doi: 10.1080/14787210.2017.1379897. Epub 2017 Sep 22. Review.

PMID:
28901793
31.

Outpatient antibiotic stewardship: Interventions and opportunities.

Dobson EL, Klepser ME, Pogue JM, Labreche MJ, Adams AJ, Gauthier TP, Turner RB, Su CP, Jacobs DM, Suda KJ; SIDP Community Pharmacy Antimicrobial Stewardship Task Force.

J Am Pharm Assoc (2003). 2017 Jul - Aug;57(4):464-473. doi: 10.1016/j.japh.2017.03.014. Epub 2017 May 16. Review.

PMID:
28526402
32.

A call to action for outpatient antibiotic stewardship.

Klepser ME, Dobson EL, Pogue JM, Labreche MJ, Adams AJ, Gauthier TP, Turner RB, Su CP, Jacobs DM, Suda KJ; SIDP Community Pharmacy Antimicrobial Stewardship Task Force.

J Am Pharm Assoc (2003). 2017 Jul - Aug;57(4):457-463. doi: 10.1016/j.japh.2017.03.013. Epub 2017 May 9.

PMID:
28499717
33.

In Vitro Assessment of Combined Polymyxin B and Minocycline Therapy against Klebsiella pneumoniae Carbapenemase (KPC)-Producing K. pneumoniae.

Huang D, Yu B, Diep JK, Sharma R, Dudley M, Monteiro J, Kaye KS, Pogue JM, Abboud CS, Rao GG.

Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e00073-17. doi: 10.1128/AAC.00073-17. Print 2017 Jul.

34.

Critical Need for Clarity in Polymyxin B Dosing.

Onufrak NJ, Rao GG, Forrest A, Pogue JM, Scheetz MH, Nation RL, Li J, Kaye KS.

Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e00208-17. doi: 10.1128/AAC.00208-17. Print 2017 May. No abstract available.

35.

Reply to Manian.

Pogue JM, Navalkele B, Kaye KS.

Clin Infect Dis. 2017 Jul 1;65(1):178-179. doi: 10.1093/cid/cix322. No abstract available.

PMID:
28419222
36.

Minocycline for the Treatment of Multidrug and Extensively Drug-Resistant A. baumannii: A Review.

Lashinsky JN, Henig O, Pogue JM, Kaye KS.

Infect Dis Ther. 2017 Jun;6(2):199-211. doi: 10.1007/s40121-017-0153-2. Epub 2017 Mar 29. Review.

37.

Clinical considerations for optimal use of the polymyxins: A focus on agent selection and dosing.

Pogue JM, Ortwine JK, Kaye KS.

Clin Microbiol Infect. 2017 Apr;23(4):229-233. doi: 10.1016/j.cmi.2017.02.023. Epub 2017 Feb 24. Review.

38.

Polymyxin B in combination with meropenem against carbapenemase-producing Klebsiella pneumoniae: pharmacodynamics and morphological changes.

Sharma R, Patel S, Abboud C, Diep J, Ly NS, Pogue JM, Kaye KS, Li J, Rao GG.

Int J Antimicrob Agents. 2017 Feb;49(2):224-232. doi: 10.1016/j.ijantimicag.2016.10.025. Epub 2016 Dec 23.

39.

Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin-Tazobactam Compared to Those on Vancomycin and Cefepime.

Navalkele B, Pogue JM, Karino S, Nishan B, Salim M, Solanki S, Pervaiz A, Tashtoush N, Shaikh H, Koppula S, Koons J, Hussain T, Perry W, Evans R, Martin ET, Mynatt RP, Murray KP, Rybak MJ, Kaye KS.

Clin Infect Dis. 2017 Jan 15;64(2):116-123. doi: 10.1093/cid/ciw709. Epub 2016 Oct 20.

PMID:
27986669
40.

Are there any ways around the exposure-limiting nephrotoxicity of the polymyxins?

Pogue JM, Ortwine JK, Kaye KS.

Int J Antimicrob Agents. 2016 Dec;48(6):622-626. doi: 10.1016/j.ijantimicag.2016.11.001. Epub 2016 Nov 11. Review.

PMID:
27876274
41.

Editorial Commentary: Colistin Dosing: Does the Fun Ever Start?

Pogue JM, Ortwine JK, Kaye KS.

Clin Infect Dis. 2016 Dec 15;63(12):1613-1614. Epub 2016 Oct 6. No abstract available.

PMID:
27794022
42.

Antimicrobial Stewardship for the Infection Control Practitioner.

Nagel JL, Kaye KS, LaPlante KL, Pogue JM.

Infect Dis Clin North Am. 2016 Sep;30(3):771-84. doi: 10.1016/j.idc.2016.04.012. Review.

PMID:
27515147
43.

Correction for Hasassri et al., An Immunocompromised Child with Bloodstream Infection Caused by Two Escherichia coli Strains, One Harboring NDM-5 and the Other Harboring OXA-48-Like Carbapenemase.

Hasassri ME, Boyce TG, Norgan AP, Cunningham SA, Jeraldo PR, Weissman SJ, Patel R, Banerjee R, Pogue JM, Kaye KS.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):5108. doi: 10.1128/AAC.01338-16. Print 2016 Aug. No abstract available.

44.

Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae.

Thaden JT, Pogue JM, Kaye KS.

Virulence. 2017 May 19;8(4):403-416. doi: 10.1080/21505594.2016.1207834. Epub 2016 Jul 6. Review.

45.

An Immunocompromised Child with Bloodstream Infection Caused by Two Escherichia coli Strains, One Harboring NDM-5 and the Other Harboring OXA-48-Like Carbapenemase.

Hasassri ME, Boyce TG, Norgan AP, Cunningham SA, Jeraldo PR, Weissman SJ, Patel R, Banerjee R, Pogue JM, Kaye KS.

Antimicrob Agents Chemother. 2016 May 23;60(6):3270-5. doi: 10.1128/AAC.03118-15. Print 2016 Jun. Erratum in: Antimicrob Agents Chemother. 2016 Aug;60(8):5108.

46.

Agents of Last Resort: Polymyxin Resistance.

Kaye KS, Pogue JM, Tran TB, Nation RL, Li J.

Infect Dis Clin North Am. 2016 Jun;30(2):391-414. doi: 10.1016/j.idc.2016.02.005. Review.

PMID:
27208765
47.

Epidemiology of Acute Kidney Injury among Patients Receiving Concomitant Vancomycin and Piperacillin-Tazobactam: Opportunities for Antimicrobial Stewardship.

Karino S, Kaye KS, Navalkele B, Nishan B, Salim M, Solanki S, Pervaiz A, Tashtoush N, Shaikh H, Koppula S, Martin ET, Mynatt RP, Murray KP, Rybak MJ, Pogue JM.

Antimicrob Agents Chemother. 2016 May 23;60(6):3743-50. doi: 10.1128/AAC.03011-15. Print 2016 Jun.

48.

Antimicrobial Stewardship Practices in Michigan Long-Term Care Facilities.

Malani AN, Brennan BM, Collins CD, Finks J, Pogue JM, Kaye KS.

Infect Control Hosp Epidemiol. 2016 Feb;37(2):236-7. doi: 10.1017/ice.2015.286. No abstract available.

PMID:
26813314
49.

Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management.

Kaye KS, Pogue JM.

Pharmacotherapy. 2015 Oct;35(10):949-62. doi: 10.1002/phar.1636. Review.

PMID:
26497481
50.

The State of Antimicrobial Stewardship in Michigan: Results of a Statewide Survey on Antimicrobial Stewardship Efforts in Acute Care Hospitals.

Collins CD, Miller DE, Kenney RM, Mynatt RP, Tiberg MD, Cole K, Sutton JD, Pogue JM.

Hosp Pharm. 2015 Mar;50(3):180-4. doi: 10.1310/hpj5003-180. No abstract available.

Supplemental Content

Loading ...
Support Center